Skip to main content
Clinical Trials/NCT01398345
NCT01398345
Completed
Phase 3

Phase 3 Study of Physical Exercise and Respiratory Training as Supportive Treatments for Patients With Severe Chronic Pulmonary Hypertension

Heidelberg University1 site in 1 country30 target enrollmentApril 2003

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Chronic Pulmonary Hypertension
Sponsor
Heidelberg University
Enrollment
30
Locations
1
Primary Endpoint
distance walked in 6 minutes
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Background

-Pulmonary hypertension (PH) is associated with restricted physical capacity, limited quality of life, and a poor prognosis because of right heart failure. The present study is the first prospective randomized study to evaluate the effects of exercise and respiratory training in patients with severe symptomatic PH.

Methods

-Patients with PH on stable disease-targeted medication will be randomly assigned to a control and a primary training group. Medication will remain unchanged during the study period. Primary end points will be the changes from baseline to week 15 in the distance walked in 6 minutes and in scores of the Short Form Health Survey quality-of-life questionnaire. Changes in WHO functional class, Borg scale, and parameters of echocardiography and gas exchange also will be assessed.

Prospects

-We hope this study will indicate that respiratory and physical training are a promising adjunct to medical treatment in severe PH.

Registry
clinicaltrials.gov
Start Date
April 2003
End Date
December 2006
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. med. Ekkehard Gruenig

Prof. Dr. med. Ekkehard Grünig

Heidelberg University

Eligibility Criteria

Inclusion Criteria

  • Patients with severe chronic PH who were stable and compensated under optimized medical therapy (such as endothelin antagonists, iloprost, sildenafil, calcium channel blockers, anticoagulants, diuretics, and supplemental oxygen) for at least 3 months before entering the study will be invited to participate.
  • Additional inclusion criteria will be age of between 18 and 75 years and World Health Organization (WHO) functional class II to IV.

Exclusion Criteria

  • Patients with recent syncope or skeletal or muscle abnormalities prohibiting participation in an exercise program won't be included.

Outcomes

Primary Outcomes

distance walked in 6 minutes

Time Frame: baseline - 15 weeks afterwards

change in quality of life as measured by the Short Form Health Survey (SF-36) questionnaire

Time Frame: baseline - 15 weeks afterwards

Secondary Outcomes

  • parameters of echocardiography(baseline - 15 weeks afterwards)
  • changes in WHO functional classification(baseline - 15 weeks afterwards)
  • parameters of gas exchange(baseline - 15 weeks afterwards)
  • Borg scale assessed immediately after completion of the stress Doppler echocardiography(baseline - 15 weeks afterwards)

Study Sites (1)

Loading locations...

Similar Trials